Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200213 | 0.79 | CYP2A6 (0.38) | CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL25819385 | 0.75 | — | — | |
| SCHEMBL31205899 | 0.73 | RIPK1 (0.40) | CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL159158 | 0.72 | CHRNB4 (0.64) | CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL159159 | 0.72 | CHRNB4 (0.64) | CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL31019621 | 0.72 | CHRNB4 (0.64) | CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL30866535 | 0.72 | CHRNB4 (0.64) | CYP2A6CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29048255 | 0.72 | PRMT5 (0.35) | PRMT5WDR77 | |
| SCHEMBL30547528 | 0.72 | PRMT5 (0.35) | PRMT5WDR77 | |
| SCHEMBL29048256 | 0.72 | PRMT5 (0.35) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | CYP2A6 3197/4885CHRNB4 4475/4885CHRNA3 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.